Key facts
- This page summarizes Rajeev M. Shah's Form 4 filing for Black Diamond Therapeutics, Inc. (BDTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 May 2023, 21:10.
Rajeev M. Shah - 16 May 2023 Form 4 Insider Report for Black Diamond Therapeutics, Inc. (BDTX)
- Reporting relationship
- Director
- Issuer ticker
- BDTX
- Reported as of
- 16 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 May 2023, 21:10:37 UTC
- Prior SEC filing
- 13 Jun 2022
- Next SEC filing
- 08 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rajeev Shah, individually
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Rajeev M. Shah filed Form 4 for Black Diamond Therapeutics, Inc. (BDTX) on 17 May 2023.
Change
- Previous filing in this sequence was filed on 13 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BDTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +16,500
- Change %
- Price
- $0.000000
- Shares after
- 16,500
- Date
- 16 May 2023
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 16,500
- Exercise price
- $1.82
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Footnote F2
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Footnote F3
The option was awarded to Mr. Rajeev Shah in connection with his service as a director of the Issuer. Mr. Shah is a Managing Partner of the Adviser. and, under his arrangement with the Adviser, Mr. Shah holds the option for the benefit of the Fund and the Nexus Fund. Mr. Shah is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
SEC remarks
Mr. Rajeev Shah, a Managing Partner of the Adviser, serves on the Issuer's board of directors.